CLYM · Climb Bio, Inc.

Track CLYM — free

$11.05 +0.11 (+1.01%) At close · Oct 5

Russell 2000 member Rebalance outlook locked

Market Cap

$655.63M

57.44M

Volume · Oct 5 1.21M Avg daily vol (3M) 1.41M

Up next

Next earnings call

Dec 31, 2026 Est · unconfirmed · in 12 wks

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$57.62M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$183.12M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+12.7%

Year over year · more shares

Price change (1Y)

+436.3%

Trailing year

Short interest

14.8%

Latest settlement · 4.5 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 15.5 · calm Equity put/call 0.59

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +13%

above

Price vs 50-day avg −21%

below

RSI (14) 32

neutral

MACD trend Negative

52-week position 58%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −29%

trailing

6-month return +25%

trailing

YTD return +176%

this year

Relative strength +13%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $14 › 200d $10 — 50d above 200d

Institutional flow Accumulating

+35% holders QoQ · +51 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

14.81% of float · ▲ +16.5% MoM · 4.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

108 holders — near 3-yr high, broad support

Squeeze score 64

elevated · 0–100

Fundamentals

Fair

EPS growth +42%

Y/Y

Free cash flow $-54.5M

Quant / Vol

risk profile

Very High

Volatility 97%

annualized · 1-yr

Max drawdown −39%

past year

ATR 8.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+13% Bullish

Price vs 50-day avg

−21% Bearish

RSI (14)

32 Neutral

MACD trend

Negative Bearish

52-week position

58% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $14 › 200d $10 — 50d above 200d

Institutional flow Accumulating

+35% holders QoQ · +51 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

14.81% of float · ▲ +16.5% MoM · 4.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

108 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $2 Now $11 · 58% Range high $18

vs 200-day avg +13% vs 50-day avg -21%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CLYM Climb Bio, Inc. this stock	$655.63M	+176.3%	—	—	14.8%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.1%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-5.9%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+589.1%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

108

% held: 98.2%
Net QoQ: +24.0M sh
Top holder: RA CAPITAL MANAGEMENT, L.…

Held Float

View

Held by Funds

Fund positions

109

View

Short & Settlement

Short Interest Rising

Shares short

8.5M

Days to cover: 4.5d
Change: +1.2M sh

View

Short Volume

Short vol %

45%

As of: Oct 5, 2026

Short Total

View

Fails to Deliver

FTD shares

279

Value: $4.4K
As of: Sep 9, 2026

View

Off-Exchange

Off-exchange %

48.8%

Week of: Aug 31, 2026

Off-exch Lit

View

Financials

Net income (FY)

$-59.9M

EPS diluted: $-0.88

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 16, 2026
This year: 22

View

Proposed Sales

Value

$1.5M

Shares: 100.0K
Filed: Sep 15, 2026

View

Exempt Offerings

Offering

$110.1M

Filed: May 4, 2026

View

Earnings & Events

Webcasts

Last webcast

Sep 16, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
CLYM	-5.9%	-28.8%	+24.9%	-3.7%	+176.3%
SPY	+1.2%	+0.6%	+11.6%	+1.6%	+13.6%
vs SPY	-7.1%	-29.4%	+13.3%	-5.3%	+162.6%

Key facts CIK 1768446 CUSIP 28658R106 13F (30d) 2 filings 2 filers Visit website Investor relations

CLYM · Climb Bio, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance